Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-11-03

Study Completion Date

2025-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics:

* in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification).
* newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

NCT06733987

Hodgkin Lymphoma

RECRUITING

Non-invasive Tumor Immunoglobulin Gene Next Generation Sequencing (IgNGS) in Diffuse Large B Cell Lymphoma (DLBCL)

NCT04237168

Lymphoma, Large B-Cell, Diffuse

UNKNOWN

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

NCT01142674

Lymphoma, T-Cell, Peripheral

COMPLETED

Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma

NCT06744075

B-cell Lymphoma Hodgkin Lymphoma

ACTIVE_NOT_RECRUITING NA

Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)

NCT04300101

Diffuse Large B Cell Lymphoma

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study aims to evaluate patients with hodgkin lymphoma in complete remission for at least 2 years and newly diagnosed (stage II b, stage III or stage IV) as they are currently characterised by a long life expectancy during which there is an increased and early incidence of non-neoplastic systemic complications as well as, of course, manifestations of secondary malignancies.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hodgkin Lymphoma in Remission

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

hodgkin lymphoma patients in complete remission for at least two years and newly diagnosed

in vitro human tissue testing of peripheral blood in hodgkin lymphoma patients in complete remission for at least two years after first-line therapy with stage II b, III or IV

Group Type EXPERIMENTAL

peripheral blood sampling

Intervention Type OTHER

It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics:

* in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification).
* newly diagnosed (stage II b, III or IV, Ann Arbor Classification).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

peripheral blood sampling

It is a monocentric and exploratory study, experimental on human tissues in vitro and similar projects do not exist in the literature. This study involves the analysis of peripheral blood in patients with hodgkin lymphoma with the following characteristics:

* in complete remission for at least two years after first-line therapy with stage II b, III or IV at onset (Ann Arbor classification).
* newly diagnosed (stage II b, III or IV, Ann Arbor Classification).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma
* Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy
* Patients of both sexes aged ≥ 18 years at enrollment
* Signature of informed consent